Intellia Therapeutics (NTLA) Other Operating Expenses (2024 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Other Operating Expenses of $904000.0 for Q1 2026, down 57.46% year-over-year from $2.1 million in Q1 2025, and down 48.46% quarter-over-quarter from $1.8 million in Q4 2025.
Intellia Therapeutics (NTLA) Other Operating Expenses (2024 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Other Operating Expenses for 3 consecutive years, with $904000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses fell 57.46% year-over-year to $904000.0; the TTM figure through Mar 2026 stood at -$2.1 million (up 94.19% YoY), while the FY2025 annual figure was -$899000.0, up 97.24% from the prior year.
- Other Operating Expenses declined to $904000.0 in Q1 2026 per NTLA's latest filing, from $1.8 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $20.4 million in Q2 2024 and bottomed at -$62.0 million in Q4 2024.
- Historically, Other Operating Expenses has averaged -$3.6 million across 3 years, with a median of $1.8 million in 2025.
- On a YoY basis, Other Operating Expenses climbed as much as 102.83% in 2025 and fell as far as 212.24% in 2025.
- Intellia Therapeutics' Other Operating Expenses stood at -$62.0 million in 2024, then jumped by 102.83% to $1.8 million in 2025, then sank by 48.46% to $904000.0 in 2026.
- Business Quant data shows NTLA's Other Operating Expenses at $904000.0 in Q1 2026, $1.8 million in Q4 2025, and -$3.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -329,000.00 |
| Mar 31, 2026 | 904,000.00 |
| Dec 31, 2025 | 1.75 Mn |
| Sep 30, 2025 | -3.44 Mn |
| Jun 30, 2025 | -1.34 Mn |
| Mar 31, 2025 | 2.13 Mn |
| Dec 31, 2024 | -62.05 Mn |
| Sep 30, 2024 | 3.06 Mn |
| Jun 30, 2024 | 20.35 Mn |
| Mar 31, 2024 | 6.07 Mn |